Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 18/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 18/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096932 | 0.90 | DDB1 (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL10168346 | 0.85 | CRBN (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL1107994 | 0.84 | DDB1 (0.53) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15502625 | 0.82 | DDB1 (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16768403 | 0.82 | CRBN (0.57) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL10168344 | 0.82 | CRBN (0.58) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL10168342 | 0.82 | CRBN (0.62) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL10168467 | 0.82 | CRBN (0.59) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL1107999 | 0.81 | DDB1 (0.55) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15502837 | 0.81 | DDB1 (0.52) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9920027-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-RE46639-E1 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9181216-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140073669-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2014-03-13 | — | — | US | disclosed |
| US-20120165536-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| US-8153659-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073669-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | DDB1 2458/4885CRBN 3542/4885IKZF3 3179/4885 |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | DDB1 820/4885CRBN 869/4885IKZF3 355/4885 |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | DDB1 2458/4885CRBN 3542/4885IKZF3 3179/4885 |
| US-20120165536-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | DDB1 2458/4885CRBN 3542/4885IKZF3 3179/4885 |
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | DDB1 2458/4885CRBN 3542/4885IKZF3 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.